Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia.
Methylation profile was analyzed in eleven cases of therapy-related leukemia (t-leukemia) for p14, p15, p16, Rb, hMLH1, hMSH2, MGMT, APC, RAR beta, DAPK, RIZ1, FHIT, and SOCS-1 genes by using methylation specific polymerase chain reaction (MSP) analysis. Six (55%) of eleven cases showed methylation of at least one gene. The average time to the development of t-leukemia after the treatment of the primary tumor was significantly shorter in patients with methylation than those without methylation (49.3 months vs. 133.2 months, P=0.044). These results suggest that hypermethylation might be involved in the development of t-leukemia.
Uehara
Eisuke
E
First Department of Internal Medicine, Kagawa Medical University, Miki-cho, Kagawa 761-0793, Japan.
Takeuchi
Seisho
S
Tasaka
Taizo
T
Matsuhashi
Yoshiko
Y
Yang
Yang
Y
Fujita
Mitsuhiro
M
Tamura
Takahiro
T
Nagai
Masami
M
Koeffler
H Phillip
HP
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects; D001854:Bone Marrow Cells / Q000378:metabolism; D018899:CpG Islands; D019175:DNA Methylation; D004260:DNA Repair; D018450:Disease Progression; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents